|
Intent-to-treat analysis
|
(n = 26)
|
|
4-week point prevalence
|
23.1%
|
|
24-week point-prevalence
|
15.4%
|
|
4-week continuous
|
15.4%
|
|
24-week continuous
|
7.7%
|
|
Completer analysis
|
(n = 20)
|
|
4-week point prevalence
|
30.0%
|
|
24-week point-prevalence
|
20.0%
|
|
4-week continuous
|
20.0%
|
|
24-week continuous
|
10.0%
|
- Intent-to-Treat Analysis: Includes all subjects enrolled in the MTSO.
- Completer Analysis: Includes only those subjects who self-reported a quit attempt on the quit day.
- Point Prevalence Abstinence: CO < 7 ppm plus no cigarettes for last 7 days on TLFB.
- Continuous Abstinence: CO < 7 ppm plus no cigarettes on TLFB plus statement of no cigarettes since the Quit Day.
- Those who did not attend the assessment visit were recorded as smoking every day.
